28Jun 2017

CLINICAL BEHAVIOUR OF METASTATIC TRIPLE NEGATIVE BREAST CARCINOMA: AN INSTITUTIONAL REVIEW.

  • Department Of Radiotherapy, Pgimer Chandigarh.
  • Department Of General Surgery, Pgimer Chandigarh.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Introduction - Triple Negative Breast Cancer (TNBC) is a type of breast cancer which is characterised by its unique molecular profile of ER,PR and HER2Neu Negativity. They are generally aggressive nature, present with different metastatic patterns and there are no targeted therapies till date. It constitutes 15-20% of all breast carcinomas. To identify the clinical behaviour of TNBC, we evaluated the 62 patients of metastatic TNBC presenting in our department in last 3 years. Methods:- Patients diagnosed with breast carcinoma (tissue diagnosis) presenting to our institution were evaluated for their ER, PR and HER2Neu status. Triple Negative (ER Negative, PR Negative, HER2Neu Negative) breast cancer subtype patients were given treatment according to the stage and patient preferences. Operable patients willing for mastectomy were operated followed by adjuvant treatment while inoperable patients were given Neo-adjuvant chemotherapy followed by surgery +/- radiotherapy. Results:- Median age of patients was 45 years (range 28-81). Majority of patients were locally advanced (82.3%) and 79% had positive nodes at the time of presentation. Initial metastasis in the cohort was around 24.2% despite most tumours being locally advanced. Bone and Liver was the most common site of metastasis at diagnosis. Upfront surgery was done in 35.48% patients while 64.52% patients were started on chemotherapy out of which 62.5% patients were amenable tosurgery. At a median follow up of 23 monthslocal recurrence was seen in 9.7% and distant metastasis in 40.32% of cases.Most common site of distant metastasis was Brain (14.52%) followed by Liver (11.29%) and Lung (11. 29%).The median disease free survival (DFS) and time to local failure in the study was 11 and 12.5 months respectively. Conclusion:- TNBCs present in younger women show variable response to chemotherapy and carry the worse prognosis, having high recurrence rate.

  1. Perou CM, S?rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747?52.
  2. Schiff R, Osborne CK, Fuqua SAWF. Clinical aspects of estrogen and progesterone In: Harris JR, Lippman ME, Morrow M, Osborne K, eds. Diseases of the Breast, 4th edn. Philadelphia, USA: Lippincott Williams and Wilkins, 2010: 408?42.
  3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721?28.
  4. Stratton MR, Breast Cancer Linkage Consortium. Pathology of familial breast cancer: diff erences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349: 1505?10.
  5. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869?74.
  6. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747?52.
  7. Thompson PA, Brewster AM, Kim-Anh D, et al. Selective genomic copy number imbalances and probability of recurrence in earlystage breast cancer. PLoS One 2011; 6:
  8. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61?70.
  9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Euro Jour Can.2009;45:228?47.
  10. Robbins SL, Kumar V, Cotran RS. Robbins and Cotran pathologic basis of disease. 8th ed. Philadelphia, PA: Saunders; 2010.
  11. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009;9(Suppl. 2):S73e81.
  12. Turner NC, Reis-Filho JS. Tackling the diversity of triple negative breast cancer. Clin Cancer Res 2013;19:6380e8.
  13. O?Brien KM, Cole SR, Tse CK, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010;16:6100e10.
  14. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418e23.
  15. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J ClinOncol 2012; 30: 1796?804.
  16. Masuda H, Baggerly KA, Wang Y, et al. Diff erential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013; 19: 5533?40.
  17. Lin NU, Bellon JR, Winer EP: CNS metastases in breast cancer. J ClinOncol 22:3608-3617, 2004
  18. Miller KD, Weathers T, Haney LG, et al: Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival. Ann Oncol 14: 1072-1077, 2003
  19. Dawood S, Broglio K, Esteva FJ, et al: Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20:621- 627, 2009
  20. Lowery AJ, Kell MR, Glynn RW, et al. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 2012;133:831e41.
  21. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008;113:2638e45.
  22. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429e34.
  23. Colzani E, Johansson AL, Liljegren A, et al. Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. Br J Cancer 2014;110:1378e84
  24. Dent R, Hanna WM, Trudeau M, et al. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer 2009;115:4917e23.
  25. Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009;115:423e8

[ Abhash Shankar, Puneet Nagpal, Budhi Singh Yadav, Divya Dahiya, Rajinder Singh and Sushmita Ghoshal. (2017); CLINICAL BEHAVIOUR OF METASTATIC TRIPLE NEGATIVE BREAST CARCINOMA: AN INSTITUTIONAL REVIEW. Int. J. of Adv. Res. 5 (Jun). 2301-2307] (ISSN 2320-5407). www.journalijar.com

Abhash Shankar
Department Of Radiotherapy,PGIMER,CHANDIGARH

DOI:

Article DOI: 10.21474/IJAR01/4672      
DOI URL: https://dx.doi.org/10.21474/IJAR01/4672

Download Full Paper

Download PDF No. of Downloads: 14 | No. of Views: 83